San Mateo, United States
NephroSant, Inc., founded in 2017, is carving a niche in the Biotechnology and Health Care sectors with their pioneering approach in kidney health. Operating out of the United States, the company is redefining how kidney injuries are detected with their slogan, "Kidney Health Redefined."
The challenge in kidney transplantation lies in the early detection of immune injury, which severely limits the life of a transplant. Addressing this critical need, NephroSant has developed a groundbreaking, cost-effective, and noninvasive assay designed to reliably monitor kidney injury, potentially changing the landscape of kidney transplant care.
The company's potential has been recognized with a $16.00M Series A investment on 16 March 2021 from notable investors including DaVita Venture Group and DigitalDx Ventures. As NephroSant continues to innovate, it represents an appealing opportunity for investors eager to support advances in healthcare technology.
